Showing results (1-10 of 214) with videos related to
Sort By:
Pageof 22
Neurosurgery Clinics of North America|November 25, 2018
Extent of Resection Versus Molecular Classification: What Matters When?Victoria E Clark, Daniel P CahillNeurosurgery Clinics of North America|November 23, 2020
Extent of Resection of Glioblastoma: A Critical Evaluation in the Molecular EraDaniel P CahillClinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2024
The Infiltrative Margins in Glioblastoma: Important Is What Has Been Left behindPhilipp Karschnia, Joerg-Christian Tonn, Daniel P CahillOncology (Williston Park, N.Y.)|August 6, 2013
Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical managementJennie W Taylor, Andrew S Chi, Daniel P CahillNeurosurgical Focus|February 5, 2013
From genomics to the clinic: biological and translational insights of mutant IDH1/2 in gliomaGavin P Dunn, Ovidiu C Andronesi, Daniel P CahillCNS Oncology|November 7, 2015
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1Daniel P Cahill, David N Louis, John Gregory CairncrossExpert Review of Anticancer Therapy|May 19, 2015
Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutationsTareq A Juratli, Daniel P Cahill, Ian E McCutcheonCurrent Neurology and Neuroscience Reports|December 11, 2014
Systemic therapy of brain metastasesHarry C Brastianos, Daniel P Cahill, Priscilla K BrastianosBiochimica Et Biophysica Acta. Reviews on Cancer|April 23, 2024
Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitorsYosuke Kitagawa, Ami Kobayashi, Daniel P Cahill, et al.Pharmacology & Therapeutics|August 24, 2017
Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomasTareq A Juratli, Nan Qin, Daniel P Cahill, et al.Pageof 22